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Rotavirus (RV) causes severe, life-threatening diarrhea, in infants, young 
children and immunocompromised adults. There are several effective vaccines 
for young children, however they are strain specific and are not protective against 
many RV strains in developing countries. Therefore, it is important to investigate 
anti-RV therapeutic agents. Our laboratory has shown arachidin-1 (A1) and 
arachadin-3 (A3) significantly inhibit RV replication in two cell lines, however the 
molecular mechanism(s) of action are not known. A synthetic molecule of A3 
(sA3) has been produced, but its’ antiviral effects have not been examined. Our 
hypothesis is that sA3 produces the same effects on RV-infected cells as natural 
A3. This study used plaque forming unit (PFU) assays to show a significant 
decrease in the amount of infectious RV particles released from arachidin treated 
cells, and tunable resistive pulse sensing technology (TRPS) revealed changes 
in the size distribution of released nanoparticles. Transmission electron 
microscopy (TEM) was utilized to observe alterations of nucleus to cytoplasm 
ratios which were confirmed with whole cell fluorescent staining techniques. This 
suggested that the arachidins modified the apoptosis and autophagy pathways. 
To support these observations, transcripts of initiator genes in both pathways 
were investigated using qRT-PCR, and the expression of two effector proteins in 
ii 
 
the apoptosis pathway were measured. Only small changes in the transcripts and 
proteins were detected which implied the regulation of other genes in the cell 
death signaling pathways that requires further examination. Both A3 and sA3 
have similar antiviral activity that results in significant decreases in the production 
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Rotavirus (RV) is a member of the Reoviridae family and is a major source 
of viral gastroenteritis affecting infants and young children (Bernstein, 2009; 
Ward, 1996) as well as in immunocompromised adults such as those with SCIDs, 
HIV, chemotherapy patients, or transplant patients (Bakare et al., 2010; 
Stelzmuller et al., 2007, Cui et al., 2015; Lee and Ison, 2014; Sugata, et al., 
2012; Yin et al., 2015; Liakopoulou et al., 2005; Anderson and Weber, 2004; 
Patel et al., 2010). RV infections are characterized by vomiting, fever, and watery 
diarrhea with symptoms usually lasting for 4-6 days (Heymann, 2015). The 
prevalent nature of RV and the serious health risks it poses have made it a major 
studied pathogen over the past 70+ years (Bernstein, 2009). Globally, by the age 
of five almost all children have been infected by RV (Ward, 1996). It is estimated 
that approximately 215,000 rotavirus deaths in children under the age of five 
occur globally each year (Tate, et al., 2016). RV is transmitted via the fecal-oral 
route and is extremely contagious (Cook, 1990). Infected persons may remain 
asymptomatic or have an acute gastroenteritis (AGE) with mild to severe 
Diarrhea and vomiting (Desselberger, 2014). AGE can lead to a massive 




Dehydration and cardiac failure are the leading causes of deaths 
associated with RV infections (Desselberger, 2011; Tate et al., 2012). The WHO 
recommends oral rehydration therapy and zinc supplementation for rotavirus-
induced diarrhea management (Gandhi et al., 2016).  
In 1973, stool samples from several severe gastroenteritis cases in young 
children at the Royal Children’s Hospital in London, England, were obtained for 
transmission electron microscopy (TEM) and spherical particles were observed 
(Bishop et al., 1973). These 1973 TEM images were the first authentication of RV 
infection in humans using TEM and led to the use of EM in the diagnosis of RV 
infections (Bishop et al., 1973). Polyacrylamide gel electrophoresis (PAGE), 
enzyme linked immunosorbent assays (ELISA), and latex agglutination tests are 
used to test for RV infections (Esona and Gautam, 2015; Heymann, 2015). After 
the visualization of RV using EM in 1973 one of Ruth Bishop’s collaborators, 
Thomas Flewett, and his team put forward the Latin name “rota”, meaning wheel, 
due to RV’s unique wheel-like microscopic appearance (Flewett and Woode, 
1978). Four years later, in 1977, the International Committee on Taxonomy of 
Viruses agreed to officially name the pathogen “rotavirus” (Mathews, 1979).  
The Centers for Disease Control (CDC) and the World Health 
Organization (WHO) report that fatality rates associated with RV have fallen 
steadily since 1980 (Bishop, 2009; Gandhi et al., 2016). This decline is attributed 




(Bishop, 2009; Jiang et al., 2010). There are two licensed attenuated RV 
vaccines: RotaTeq® (Merck) and RotaRix® (GlaxoSmithKline). Rotarix® is an 
attenuated human RV vaccine made with a tissue-culture-adapted human strain, 
and RotaTeq® is a bovine (WC3)-human reassortment vaccine composed of 5 
strains, each containing a human rotavirus gene (Angel et al., 2007). These 
vaccines only protect against specific RV strains (Leshem et al., 2014). Recently 
a new attenuated RV vaccine, Rotavac®, was recently released in India by 
Hyderabad-based Bharat Biotech International (Bhandari et al., 2014; John, 
2014). Rotavac® only protects against an RV strain that is a common cause of 
severe diarrhea in children in India (Bhandari et al., 2014).   
Vaccines represent a major means in which to prevent the severe 
negative outcomes of rotavirus infection, especially in impoverished regions 
where resources and access to care may be limited (Madhi et al., 2016). 
However, the vaccines efficacies are dependent on the timing of vaccination, and 
are designed to protect against common RV strains in specific areas of the world 
and therefore do not provide universal protection (Glass, 2006; John, 2014). 
Neither natural RV infections nor RV vaccines provide full protection from future 
infections (Centers for Disease Control and Prevention, 2017). Vaccinated 
children are much less likely to get sick from rotavirus, and if they do, their 
symptoms are usually much less severe than unvaccinated children (Centers for 




Mature RVs are segmented double-stranded RNA viruses (Patton, 2012). 
RV particles (virions) are approximately 75 nanometers (nm) in diameter, non-
enveloped, and have three concentric icosahedral protein layers that encapsulate 
11 double stranded RNA segments (Estes, 2001; Heymann, 2015). Each RNA 
segment codes for one viral protein (VP) except for gene segment 11 which 
codes for two proteins (Estes, 2001). There are six viral structural proteins (VP1-
VP4, VP6 and VP7) and six nonstructural proteins (NSP1-NSP6) (Matthijnssens, 
et al., 2008). VP4 is then cleaved into two polypeptides, VP5 and VP8 (Jayaram 
et al., 2004). 
These proteins function either as a structural component of the virus 
particle (VP) or as a nonstructural protein (NSP) which is involved in various 
aspects of the viral replication cycle (Jayaram et al, 2004). The inner core of the 
RV particle is made up of 60 dimers of VP2 and encloses the complete viral 
genome as well as viral RNA dependent RNA polymerase, VP1 and the capping 
enzyme VP3 (Desselberger, 2014; Jayaram et al., 2004; Patton, 1995). The 
intermediate capsid layer is composed of VP6 and is arranged in a lattice form 
with 260 trimers forming the icosahedral layer (Desselberger, 2014; Payne et al., 
2006).  
In immature virus particles, the outside protein coats are made from only 
VP6 (Payne et al., 2006). These immature particles are known as noninfectious 




participates in communication with the inner VP2 layer in addition to the outer 
proteins, VP4, and VP7 (Payne et al., 2006). Rotavirus particles contain large 
channels that breach through the VP7 and VP6 layers (Payne et al., 2006). 
These channels facilitate the passage of aqueous materials through the capsid 
(Payne et al., 2006). When an RV particle contains both VP4 and VP7 it is 
considered a triple layered particle (TLP) and is considered infectious (Payne et 
al. 2006). The outermost layer consists of an icosahedral capsid made of VP7, a 
glycoprotein, with 60 projecting spikes that are made up of VP4 dimers (Payne et 
al., 2006). These spikes are required by the virions for efficient cell entry (Payne 
et al., 2006). When RV attaches to the host’s cell surface VP4 is cleaved by the 
small intestine enzyme trypsin (Estes et al., 1981). This produces a 
conformational change and the production of VP5 and VP8 which are necessary 
for viral entry into the host cell (Estes et al., 1981). 
 The process of viral entry is still not wholly understood. The process of 
receptor mediated endocytosis was the first accepted method of RV entry 
(Bernstein, 2009). It has also been found that low calcium levels in endosomes 
make it possible for direct membrane penetration via the solubilization of the 
outer capsid protein VP7 (Desselberger, 2014).  
The newly formed transcriptionally active DLPs are released into the 




structures called viroplasms where viral replication begins to take place (Patton, 
1995).  
Viroplasms vary in size and shape depending on the replication cycle but 
are usually located adjacent to the nucleus (Desselberger, 2014). Viroplasms 
produce new DLPs which then bud into the endoplasmic reticulum (ER) by the 
attachment to a nonstructural protein (NSP4) (Desselberger, 2014; Greenberg 
and Estes, 2009). As VP4 and VP7 assemble, the ER membranes are removed, 
resulting in a mature TLP (Greenberg and Estes, 2009). TLPs are released in 
epithelial cells via budding (Gardet et al., 2006).  
There are many challenges in the attempt to combat RV. One major 
challenge is posed by reassortment, which leads to new RV strains (Patton, 
2012). All of the 11 rotavirus gene segments are responsible in creating rotavirus 
diversity in nature (Matthijnssens, et al., 2008). Reassortment can take place 
during co-infections producing novel RV strains (Ball, et. al., 2005; Patton, 2012; 
Yakshe et al., 2015). The differences in the efficacies of vaccines in developed 
and developing countries are also a major challenge (Lopman et al, 2012).  
Recent studies in the Parr laboratory have shown that two stilbenoids 
Arachidin-1 and -3 (A1 and A3) (natural products from peanut hairy root cultures) 
significantly reduce the production of infectious RV particles and decrease viral 
replication (Ball et al., 2015). These findings demonstrate the potential for the 




 Stilbenoids are secondary metabolites which act as phytoalexins (a 
substance that is produced by plant tissues in response to contact with a parasite 
and that specifically inhibit the growth of that parasite) which are produced by 
plants including grape, berry, and peanut plants in response to pathogens and 
are derived from the phenylpropanoid/ acetate pathway (Huang et al., 2010; 
Moss et al., 2013). Phytoalexins tend to accumulate rapidly in areas of 
pathogenic infection and demonstrate anti-oxidative/anti-pathogenic properties 
(Chong et al., 2009; Jeandet et al., 2010).  
 Resveratrol is a stilbenoid commonly found in grapes used for making red 
wine, has received much attention due to its wide range of biological activities 
and potential health benefits (Berardi et al., 2009; Moss et al., 2013). These 
benefits may include: anti-oxidative-, anti-inflammatory-, cardioprotective-, 
antiviral-, anticancer-, and anti-aging-properties (Huang et al., 2010, Sobolev et 
al., 2006, Velayudhan et al., 2014).  
 Many in vitro and in vivo studies have demonstrated significant biological 
effects of resveratrol (Berardi et al., 2009; Nakamura et al., 2010; Palamara et 
al., 2005). However, at times it lacks biological activity due to its limited oral 
bioavaibility (Gambini et al., 2015; Vitaglione et al., 2005). Rapid absorption and 
metabolism leading to the formation of various metabolites such as resveratrol 




responsible for resveratrols curbed oral bioavailability (Gambini et al., 2015; 
Vitaglione et al., 2005).  
Resveratrol strongly inhibits the replication of influenza virus, improves 
survival, and decreases pulmonary viral infectivity titers in influenza virus-infected 
mice (Palamara et al., 2005). Furthermore, resveratrol exhibits no toxic effects in 
vitro or in vivo (Palamara et al., 2005). However, another study testing the effects 
of different concentrations of resveratrol on polyomavirus showed cytotoxicity in a 
time- and dose-dependent manner and inhibition of polyomavirus DNA synthesis 
(Berardi et al., 2009). Another study identified resveratrol derivatives with potent 
anti-HSV-1 and HSV-2 activity showing antiherpetic activity at single-digit 
micromolar concentrations (Chen et al., 2012). 
 In peanuts, the some of the known stilbenoids are prenylated, having an 
isopentenyl moiety as in A1 and A3 (Sobolev et al., 2006). Studies have shown 
that A1 has a higher efficacy in inducing programmed cell death in leukemia HL-
60 cells (Huang et al., 2010). These results show the potential use of A1 as an 
anti-cancer drug.  
Once peanut (Arachis hypohaea) hairy root cultures are exposed to abiotic 
(environmental) and biotic (caused by living organisms) stresses they produce 
stilbenoids including:  resveratrol, piceatannol, A3 and A1 (Chong et al., 2009). 
These stilbenoids have been shown to possess anti-inflammatory, anti-cancer 




A synthetic version of A3 (sA3) has been produced by the laboratory of Dr. 
Medina-Bolivar (personal communications). A U.S. utility patent 9,981,895 was 
awarded on May 29, 2018 titled “Compositions and Methods of Synthesizing 
Arachidin-3 from Resveratrol”. Briefly, organic synthesis using primary 
alkylamines or primary hydroxyalkyl amines, or carboxy amines with natural 
carboxylic acids as catalysts to react isovaleraldehyde with trans-resveratrol is 
utilized in the production of sA3 (Clayton and Bandy, 2018). An azeotropic 
mixture comprising toluene with pyridine, n-butanol, n-propanol, 2-propanol, 2-
methyl-1-propanol, or other alcohols that form an azeotrope with toluene used as 
the organic solvent in which the synthesis is carried out (Clayton and Bandy, 
2018). Column chromatography (neutral), high performance liquid 
chromatography (HPLC), high performance counter-current chromatography, thin 
layer chromatography (TLC), nuclear magnetic resonance spectroscopy (NMR), 
and infrared spectroscopy (IR) are all utilized as purification and qualification 
analysis techniques in sA3 production (Clayton and Bandy, 2018).   
 One study suggests that the enhanced therapeutic activity of stilbenoids is 
likely the result from the increased ability to dissolve fats, oils, and non-polar 
solvents which is imparted by single or multiple groups present within their 
structure (Huang et al., 2010). It has been proposed that the greater lipophilicity 
of prenylated trans-Resveratrol (t-Res) analogues may allow for easier 




may increase access and association with potential membrane-bound molecular 
targets responsible for the beneficial activities of these compounds (Huang et al., 
2010). Another study suggests that the lipophilic side chain (3-methyl-1-butenyl 
group) might hinder the addition of glucuronic acid to a substrate and thereby 
enhance the bioavailability of the analogues (Brents et al., 2012). Additionally, A3 
exhibits higher biological activities both in vitro and in vivo when compared to 
resveratrol, also demonstrating antiviral activity (Ball et al., 2015; Yang et al., 
2015).  
Our hypothesis is that the addition of the sA3 to RV-infected HT29.f8 cells 
decreases the amount of infectious viral particles in an infection and produces 
the same effects on the host cell as the natural A3. My hypothesis is that the 
addition of either the natural A3 or sA3 to a human RV-infected HT29.f8 cell line 
effects the infected host and effects the maturation of infectious RV particles. 
This results in the decrease of infectious viral particles produced, changes in the 
host cell ultrastructure, and regulation of the host gene transcripts.  This 
hypothesis will be tested using four objectives:  
(1) Establish that the viability of the cells are not affected with the addition of 20 
µM final concentration sA3 by performing cell viability assays;  
(2) Measure the progeny infectious RV particles using plaque forming unit (PFU) 




(3) Visualize the effects of treatments on the cells using TEM, whole cell 
fluorescent staining, and morphometric analysis;     
(4) Determine the effects of treatments on gene expression and regulation of cell 







Materials and Methods 
 
Cells, MycoFind™ Mycoplasma PCR detection kit, and virus  
MA104 cells were obtained from ATCC (Rockville, MD) and HT29.F8 
cells, a spontaneously polarizing cell line, were derived from the parent human 
adenocarcinoma (HT29) intestinal line (Mitchell & Ball, 2004). RV Wa (G[1] P[8] 
genotype) (Matthijnssens et al., 2008) was amplified, viral titers determined to be 
3.66E+11 PFU/mL by plaque forming unit (PFU) assays using MA104 cells, and 
stored at -80°C. Stilbenoid efficacy against RV was tested using HT29.f8 cells 
obtained from Dr. Judith Ball (Texas A&M University, College Station, TX).  The 
cell line was maintained in Dulbecco's Modified Eagle Medium (DMEM; Genesee 
Scientific, San Diego, CA) supplemented with 7.5% fetal bovine serum (FBS; 
Caisson, Smithfield, UT), L-glutamine (2 mM) (Caisson, Smithfield, UT), 
penicillin-streptomycin (100 µg/mL) (Caisson, Smithfield, UT) and non-essential 
amino acids (Caisson, Smithfield, UT) as a 100X solution. The amino acids were 
used at a 1X concentration of 100 µM each.) (Mitchell & Ball, 2004).  The cell 
lines were confirmed to be free of mycoplasma contamination using the PCR 




Briefly, the cell lines were cultured for 2 weeks in media lacking Pen/Strep. 
1 mL of supernatants from each cell line was transferred into sterile labelled 1.5 
mL microfuge tubes and centrifuged at 500 x g for 5 minutes in order to pellet 
cellular debris. The supernatants were then transferred into fresh sterile 1.5mL 
microfuge tubes and centrifuged at 14,000 x g for 15 minutes. The cell pellets 
were re-suspended with 100 µL of DNA free water. The test samples, positive 
control, and negative control were prepared as per Table 1.  
 







Rehydration Buffer 23 µL 23 µL 23 µL 
Sample 2 µL   
DNA-free water  2 µL  
Fresh Cell Culture 
Medium  
  2 µL 
 
The contents of the test sample tubes, positive control tube, and negative 




components were allowed to dissolve by incubating the tubes for 5 minutes at 
25°C. The thermal cycling parameters laid out in Table 2 were used.  
 
Table 2. Thermal Cycling parameters used for PCR Mycoplasma Test Kit I/C 
1 cycle 95° for 2 minutes 
40 cycles 94°C for 30 seconds  
55°C for 30 seconds  
72°C for 40 seconds  
Hold  4°C  
 
The tubes were quickly tap-spun and 8 µL of the resulting products were 
run on a 1.5% agarose gel (0.75g Molecular Biology Certified agarose (IBI 
Scientific, Peosta, CA), 50 mL 1X TAE (Apex BioResearch Products, Genesee 
Scientific, San Diego, CA), 5 µL GelRed dye (Biotium Inc., Fremont, CA)) 
alongside the Apex 100 bp-Mid DNA marker (Genesee Scientific, San Diego, 
CA) for 1 hour at 100 volts using the BioRad PowerPac and Mini-Sub Cell GT 
(BioRad Laboratories, Hercules, CA). The gel was visualized on the Typhoon 
FLA 9000 (GE Healthcare Life Sciences, Uppsala, Sweden) using the following 





 Bio-production of stilbenoids in peanut hairy root cultures 
Natural A3 were purified from methyl-β-cyclodextrin (CD)-elicited peanut 
(A. hypogea) hairy root cultures as recently described (Abbott et al., 2010; 
Condori et al., 2010; Yang et al., 2015).  Briefly, 9-day peanut hairy root cultures, 
line 3 (Condori et al. 2010), were elicited with methyl-β-cyclodextrin (fresh MSV 
medium with 9 g/L methyl-β-cyclodextrin (Cavasol® W7 M)) (Medina-Bolivar et al. 
2007; Medina-Bolivar et al. 2010). Cultures were incubated in the dark at 28°C for 
an additional 72 hours to induce synthesis and secretion of stilbenoids into the 
culture medium (Abbott et al., 2010; Yang et al., 2015).  After the elicitation 
period, the culture medium was removed from each flask and combined. This 
pooled medium was mixed with an equal volume of ethyl acetate in a separator 
funnel to extract the stilbenoids as described previously (Jose Condori et al., 
2010).  The ethyl acetate phase was recovered and dried in a rotavapor (Buchi 
Corp., New Castle, DE), and A3 was purified from the extract with HPCCC.  
Fractions were collected every 30 seconds, dried in a speed-vac and selected 
fractions were checked for purity by mass spectrometry using an UltiMate 3000 
ultrahigh performance liquid chromatography (UHPLC) system (Dionex, Thermo 
Scientific, Waltham, WA) coupled with a LTQ XL linear ion trap mass 
spectrometer (Thermo Scientific, Waltham, MA) as previously described (Marsh 
et al., 2014).  HPCCC fractions containing A3 with over 95% purity based on 




used for viral assays.  The dry mass of the purified stilbenoids were reconstituted 
in 0.02% DMSO with 1 µg/mL Worthington trypsin (WT) (Worthington 
Biochemical, Lakewood, NJ) in MEM medium.  
A synthetic version of A3 (sA3) has been produced by the laboratory of Dr. 
Medina-Bolivar (personal communications). A U.S. utility patent application was 
filed on March 29, 2016 titled “Compositions and Methods of Synthesizing 
Arachidin-3 from Resveratrol”. Briefly, organic synthesis using primary 
alkylamines or primary hydroxyalkyl amines, or carboxy amines with natural 
carboxylic acids as catalysts to react isovaleraldehyde with trans-resveratrol is 
utilized in the production of sA3 (Clayton and Bandy, 2018). An azeotropic 
mixture comprising toluene with pyridine, n-butanol, n-propanol, 2-propanol, 2-
methyl-1-propanol, or other alcohols that form an azeotrope with toluene used as 
the organic solvent in which the synthesis is carried out (Clayton and Bandy, 
2018). Column chromatography (neutral), high performance liquid 
chromatography (HPLC), high performance counter-current chromatography, thin 
layer chromatography (TLC), nuclear magnetic resonance spectroscopy (NMR), 
and infrared spectroscopy (IR) are all utilized as purification and qualification 






 RV Infections in HT29.f8 Cells 
To test the biological activity of A3 and sA3 on RV infections in HT29.f8 
cells, the cells were grown to 80% confluence in T25 tissue culture flasks 
(Corning Life Sciences); starved for fetal bovine sera 8 hours prior to infection, 
and then infected with RV Wa as previously described (Arnold et al., 2009; Ball et 
al., 2015; Yakshe et al., 2015).  Briefly, Wa RV stock was sonicated 10 min using 
a cup horn attachment and ice bath in a Misonix Sonicator 3000 (Misonix, Inc., 
Farmingdale, NY) and incubated in serum-free DMEM with 10 μg/mL trypsin 
(WT) for 45 min at 37°C. The activated viral inoculum was incubated with the 
cells for 1 hour at 37°C in 5% CO2 at an MOI of 2. At the scheduled collection 
times, cells were washed with Dulbecco’s PBS (Caisson Laboratories, Smithfield, 
UT) and released from the flasks using a 0.25% trypsin (0.25% trypsin in HBSS, 
Caisson Labs (North Logan, UT)). The supernatants were collected, clarified at 
10 000 x g for 5 min, and stored at -80°C for plaque assays and TRPS analysis 
(see below).  The cells were washed in 1X cold Dulbecco's PBS   (Caisson 
Laboratories, Smithfield, UT), fixed with 5% glutaraldehyde and used for TEM 








Toxicity of A3 and sA3 to HT29.f8 cells: Trypan Blue cell exclusion viability 
assay 
Viability assays were performed with RV alone, RV + 0.02% DMSO 
(bioWORLD, Dublin, OH), RV with 20 µM A3 or sA3,  20 µM A3 alone, 20 µM 
sA3 alone, cells without treatments (NV, no virus), and cell with 0.02% DMSO 
using the trypan blue cell exclusion assay (Ball et al., 2015; Freshney, 1994).  
Briefly, HT29.f8 cells were grown to 80% confluence in 6-well tissue culture 
plates (Corning Life Sciences, Corning, NY); starved from fetal bovine sera 8 
hours prior to the addition of 0.02% DMSO, 0.02% DMSO with 20 µM 
concentrations of the arachidins, RV (MOI 2), and RV (MOI 2) with 20 µM 
concentrations of the arachidins.  At 18 hours after the treatments, a suspension 
of ~106 cells/mL was diluted 1:1 with a 0.4% trypan blue solution (Sigma-Aldrich, 
St. Lois, MO. T8154, Lot RNBC8659), and loaded onto a Neubauer-improved 
hemocytometer (Paul Marienfeld Gmbh & Co. Kg., Lauda-Königshofen, 
Germany). Each of the four corner squares was used for counts. Any cell sitting 
on or outside a division line was not counted. The number of stained dead cells 
and total number of cells were counted, and the calculated percentage of live 
cells was reported. Each treatment was performed in triplicate, Data were 
statistically analyzed in Microsoft Office Excel 2016 software using one-way 




P <0.05) with Bonferroni’s post hoc test to correct for multiple comparisons (P < 
0.004545). 
 
Production of infectious virus particles with the addition of A3 or sA3 
6-well, flat bottom tissue culture plates (Olympus plastics, tissue culture 
plate, 6-well, flat bottom, cat. #25-105, Genesee Scientific) in were seeded with 
approximately 0.5X106 MA104 cells/well with 3mL complete MEM. Cells were 
grown to confluency (approximately 2 days). Plaque forming unit (PFU) assays 
were performed in triplicate as previously described (Arnold et al., 2009; Ball et 
al., 2015; Yakshe et al., 2015).  Briefly, 0.5 mL of 10-fold dilutions of RV alone 
and RV with 20 µM of A3 or sA3 supernatants collected at 18hpi from previous 
infections were added to serum starved MA104 cells for 1 hour at 37°C, 5% CO2. 
The virus inoculum was removed and the wells were washed gently with pre-
warmed Dulbecco’s PBS (GE Healthcare Life Sciences, HyClone Laboratories, 
Logan, Utah) after which 3 mL of a medium overlay consisting of a 1:3 mixture of 
5% agarose (Apex Low Melting Point Agarose, Genesee Scientific Inc., San 
Diego, CA) and complete serum-free MEM with a 1:100 dilution of 100X 
Pen/Strep was overlaid and allowed to set and incubated at 37°C in 5% CO2 for 
approximately 1-2 days or until plaques became visible.  A neutral red overlay 




μg/mL neutral red was prepared and 1 mL per well of stain overlay was added on 
top of the first agarose/medium overlay and allowed to set. The six-well plates 
were incubated at 37°C until plaques were clearly visible (approximately 12 to 36 
hours).  The individual plaques were counted, and the titers were calculated as 
follows:   
 
Number of plaques x 1/dilution factor x 1/ (mL of inoculum) = PFU/mL 
 
Plaque forming assays were performed four times in triplicate as outlined 
above.  Data were expressed as mean  SD, and comparisons were statistically 
evaluated by analysis of variance (ANOVA) and two-tailed Student’s t tests using 
Microsoft Excel 2016 software (significance level, P < 0.05). 
 
Quantification of nanoparticles and size distribution by TRPS analysis 
TRPS analysis using the qNano system (Izon Science, Cambridge, MA) 
was performed on the RV-infected cell supernatants to display the concentration 
of virus particles/mL, diameter of RV particles and size distribution of particles.  
TRPS is based on a coulter counter that is composed of two fluid reservoirs filled 




containing a nanopore (Kozak et al., 2011; Weatherall et al., 2016).  When an 
electrical field is applied across the pore, the resistance to the resulting ionic 
current is indirectly proportional to the cross-sectional area of the pore.  When a 
non-conducting particle passes through the pore, the increase in resistance is 
proportional to the particle volume relative to pore size. This change in resistance 
is detected as a pulse in an ionic current. The pulse frequency is proportional to 
particle flow rate and particle concentration (DeBlois, 1970). This system 
provides a quick and accurate method with which to measure sizes of individual 
nanoparticles and their volume in a solution.  All qNano experiments were 
performed using the manufacturer's established protocols (Bo et al., 2014; Jones, 
2015; Vogel et al., 2011).  Briefly, samples were purified using a qEV 10 size 
exclusion column from Izon (Izon Scientific, Cambridge, MA) (containing resin 
with approximately 75nm pore size). The samples were suspended in Dulbecco’s 
PBS with 0.025% Tween 20 to reduce particle aggregation and facilitate the 
wetting of the nanopore. A 1:1000 dilution of the sample was placed on the 
qNano size-tunable nanopore (NP100, Izon), and each sample was measured as 
a transient change in the ionic current flow using the custom assistant application 
in IZON proprietary software v3.2.2.268 (Izon). Samples are driven through the 
nanopore by applying a combination of pressure and voltage, and each particle 
causes a blockade signal which is detected and measured by the application 




(Vogel et al., 2012), and the blockade frequency is used to determine particle 
concentration (Roberts et al., 2012). These values are converted into particle 
properties (size and concentration, respectively) by calibration with particles of 
known size and concentration (CPX100B, Izon). The size distribution and 
concentration analysis was performed using IZON proprietary software 
v3.2.2.268 (Izon). 
 
 TEM morphometric analysis of arachidin treated RV-infected HT29.f8 cells 
TEM analysis was performed on RV-infected HT29.f8 cells to visualize the 
effects of A3 and sA3 on progeny virus and cellular morphology as described by 
Wright (2000).  Briefly, RV-infected HT29.f8 cells with and without 20 µM A3 or 
sA3 were incubated for 16 and 18 hpi, washed with Dulbecco’s PBS and then 
trypsinized.  Cells were pelleted and fixed with 5% glutaraldehyde (Electron 
Microscopy Sciences, Hatfield, PA) and refrigerated overnight at 4°C. The cells 
were post-fixed with 2% osmium tetroxide (Electron Microscopy Sciences, 
Hatfield, PA) followed by an overnight incubation in a uranyl acetate solution 
(Electron Microscopy Sciences, Hatfield, PA). Cells were dehydrated with a 
graded ethanol series (2x wash with deionized water at 10-15 minute intervals, 
followed by ethanol series at 10-15 minute intervals: 20% EtOH, 40% EtOH, 60% 




Microscopy Sciences, Hatfield, PA). Acetone was used for the transitional 
solvent, after which the samples were infiltrated and embedded in Spurr’s resin  
(Electron Microscopy Sciences, Hatfield, PA) (70% Spurr’s resin, 30% Acetone, 
replaced with 100% Spurr’s resin after 8 hours and polymerized at 70°C 
overnight in a Robbins Scientific Model 400 Hybridization Incubator (Robbins 
Scientific Corporation, Sunnyvale, CA)). Ultra-thin sections (~50-80 nm) were 
obtained with an RMC MT-X ultra-microtome (Boeckeler instruments, Tucson, 
AZ) and stained with uranyl acetate and lead citrate (Electron Microscopy 
Sciences, Hatfield, PA). Samples were examined and photographed  with a 
Hitachi H-7000 transmission electron microscope operating at 75 KeV (Wright, 
2000), negatives were digitized at 600 dpi using the HP Scanjet G4050 (HP Inc., 
Palo Alto, CA), and image analysis was performed using Macnification Version 2 
(Orbicule, Inc., www.orbicule.com). The mean ratio of the cell nucleus to 
cytoplasm was determined using 10 micrographs of cells from each treatment to 
compare between test and control groups. Data were statistically analyzed in 
Microsoft Office Excel 2016 software using one-way analysis of variance 
(ANOVA) and two-tailed Student’s t tests (significance level, P <0.05) with 






Whole cell fluorescent staining for morphometric analysis  
The nucleus and plasma membranes of HT29.f8 cells were fluorescently 
labelled to determine the ratios of the nucleus to cytoplasm of whole cells to 
compare to the nucleus to cytoplasm ratios obtained with TEM.  Briefly, cells 
were grown to 80% confluence in 8-well slides (Lab-Tek Chamber Slide System, 
Nunc, Inc. Naperville, IL) and RV-infected and treated with the arachidins as 
described above (RV alone, RV with 20 µM A3 or A3, 20 µM sA3 alone, or 20 µM 
sA3 alone, and cells without treatments (NV-no virus). At 18 hpi, the cells were 
washed with PBS 1x one time at 25°C, and then fixed with 1% Glutaraldehyde 
(Electron Microscopy Science, Hatfield, PA) for one hour at 25°C in a fume hood 
(Harlow and Lane, 1988). Following fixation, the cells were washed twice with 
PBS 1x at 25°C. The Image-IT™ LIVE Plasma Membrane and Nuclear Labeling 
Kit (I34406) (Molecular Probes, Invitrogen detection Technologies, Eugene, OR) 
was used to label the cells. Briefly, one solution for the single step staining for 
both stains was prepared by adding 5.0 µg/mL Alexa Flour 594-labeled wheat 
germ agglutinin and 1 µM Hoechst 33342 stain into 1x PBS. Two hundred µLs of 
the labelling solution was added to each well in 8-well chambered slides, and 
incubated for ten minutes at 25ºC, removed and the cells were washed twice with 
PBS 1x, and mounted in PBS 1x. The microscopic analysis was carried out using 
the Olympus BX50 with DP Manager System compound light microscope with 




480-550nm, dichroic mirror DM 570nm, barrier filter 590nm) and Hoechst 33342 
(Excitation 330-385nm, dichroic mirror DM 400nm, barrier filter BA420nm) with 
the DP71 camera (Olympus Corporation, Shinjuku, Tokyo, Japan) equipped with 
x 40 and X100 objectives. The images were digitized using the DP Controller 
software (Olympus Corporation), and the pixels of the nucleus and whole cell 
were measured using Macnification Version 2 (Orbicule, Inc., www.orbicule.com). 
Excel was used to determine the mean nucleus to cytoplasm ratio of the cells (N 
= 50 cells of each treatment). Data were statistically analyzed in Microsoft Office 
Excel 2016 software using one-way analysis of variance (ANOVA) and two-tailed 
Student’s t tests (significance level, P <0.05) with Bonferroni’s post hoc test to 
correct for multiple comparisons (P <0.0033). 
 
Quantification of Transcripts for Cell Death Pathway Genes in HT29.f8 Cells 
QuantiFluor dsDNA System 
 The QuantiFluor dsDNA System contains a fluorescent DNA-binding dye 
(504nmEX/531nmEM) that enables sensitive quantitation of small amounts of 
double-stranded DNA (dsDNA) in a purified sample. Before conducting the qRT-
PCR studies a QuantiFluor assay standard curve was conducted to determine 
accuracy of pipettes and handling. Briefly, a working solution was prepared by 




Quantifluor dsDNA de working solution. A standard curve was prepared resulting 
in 0.05-200ng/well as shown in table 3.  
 
Table 3. Preparing Recommended dsDNA standard Curve Samples. 
Standard Volume of dsDNA 
Standard (µl) 




A 20 80 20 
B 25 of standard A 75 5 
C 25 of standard B 75 1.25 
D 25 of standard C 75 0.31 
E 25 of standard D 75 0.078 
F 25 of standard E 75 0.02 
G 25 of standard F 75 0.005 
 
200µl of QuantiFluor dsDNA Dye working solution was pipetted into each 
well intended for an unknown, blank or standard. Each standard and unknown 
was performed in triplicate. 10 µl of the dsDNA standards prepared as in table 3 
was dispensed into the plate using a multichannel pipet. For the blanks, 10 µl of 
1X TE buffer was loaded into the blank wells. 10-fold dilutions of the unknown 




tunable microplate reader (Molecular Devices, Sunnyvale, CA) and the plate was 
shaken for 10 seconds to facilitate thorough mixing. The plate was incubated at 
room temperature for 5 minutes protected from light. The fluorescence 
(504nmEX/531nmEM) was measured using VERSAmax tunable microplate reader 
(Molecular Devices, Sunnyvale, CA) and the SoftMax Pro v5 software (Molecular 
Devices Corp., Sunnyvale, CA). The dsDNA was calculated as follows: the 
florescence of the blank sample (1X TE Buffer) was subtracted from all of the 
standard and unknown samples. The corrected data from the DNA standards 
was then used to generate a standard curve of fluorescence versus DNA 
concentration. The unknown samples DNA concentration was then determined 
from the standard curve and multiplying the resulting number by the dilution 
factor if applicable.  
 
Efficiency Assay 
 Robust and accurate qPCR assays are typically associated with high PCR 
efficiencies (Bustin et al., 2009). The ∆∆Ct method was utilized to determine 
differences in concentrations between samples and is based on normalization 
with a reference gene(s) (Bustin et al., 2009). The ∆∆Ct method assumes a 
uniform PCR amplification of 100% across all samples (Rao et al., 2014). 




comparison to be accurate (Bustin et al., 2009). Efficiencies usually are not 
exactly 100% due to factors such as the presence of PCR inhibitors or enhances, 
RNA extraction, and different uses of probes, primers, and enzymes (Rao et al., 
2014). Efficiencies of 90-100% are considered usable for publication (Rao et al., 
2014). Amplification efficiency should be determined from the slope of the log-
linear portion of the calibration curve (Bustin et al., 2009).The equation: 
 
PCR efficiency= 10-1/slope -1 
 
In which the logarithm of the initial template concentration is plotted on the x axis 
and the Ct is plotted on the y axis was used to determine efficiencies. The 
theoretical maximum of 1.00 (100%) indicates that the amount of product 
doubles with each cycle (Bustin et al., 2009).  
RNA was extracted from each experimental set described above. The 
ZYMO Research Quick-RNA Miniprep (Catalog number R1054) (Zymo research 
corp., Irvine, CA) was used to extract and purify total RNA according to the 
manual protocol.  cDNA was synthesized using the ThermoFisher cDNA 
synthesis kit (Thermo Fisher Scientific, Inc., Waltham, MA). Efficiency assays 
were run using the suggested Luna Universal Probe and qPCR Master Mix (New 




Briefly, the samples were lysed and homogenized by adding 600 µL of 
lysis buffer directly to each T75 flask, rocking gently, transferring cells to 1.5 mL 
microfuge tubes, and passing each sample through a clean 26G3/8 syringe 5-10 
times. Sample cleaning and gDNA removal was performed by centrifuging the 
samples at 12 000 x g for 1 minute, transferring the samples to spin-away filters 
(yellow) in a collection tube and centrifuging at 12 000 x g for 1 minute. The flow-
through was used for RNA purification. RNA purification was performed by 
adding 1 volume of 200-proof ethanol to each RNA sample and mixing well. The 
samples were then transferred to Zymo-spin III CG columns (green) in collection 
tubes and centrifuged at 12 000 x g for 30 seconds. In-column DNase I treatment 
was then performed: The samples were washed with 400 µL RNA wash buffer, 
centrifuged at 12 000 x g for 30 seconds, the flow-through discarded, and then 
80 µL of DNase I treatment mix (5 µL DNase I, 75 µL DNA digestion buffer) was 
added to each column matrix and incubated at room temperature for 15 minutes 
followed by a 12 000 x g centrifugation for 30 seconds. The samples were 
washed with 400 µL RNA prep buffer and centrifuged at 12 000 x g for 30 
seconds. 700 µL of RNA wash buffer was added to each sample and they were 
centrifuged at 12 000 x g for 30 seconds. A further wash was performed using 
400 µL RNA wash buffer and a centrifugation at 12 000 x g for 2 minutes. The 
columns were places in RNase-free tubes and 50 µL of DNase/RNase free 




on each sample they were spun at top speed for 30 seconds, the flow through 
was recovered and re-applied to the columns for a further spin at top speed for 
30 seconds. Total RNA was analyzed using a full spectrum analysis at 240 nm- 
300 nm in the Cary 50 spectrophotometer (Agilent, Corp., Santa Clara, CA). The 
total RNA was stored at -80C for future studies. A conversion factor of 40 μg/mL 
was used to convert the A260 to concentration and the value of 10 corrected for 
path length of 0.1 mm (Sean and Wiley, 2008). The concentration of RNA was 
calculated using the formula as follows:  
 
Concentration of RNA= A260 x 40 μg/mL x 10 x Dilution factor 
 
 cDNA was then synthesized using the Thermo Scientific Verso cDNA 
Synthesis Kit from each experimental set using 500 ng of purified total RNA.  A 
Master Mix was prepared as described in the manufacturer’s protocol as shown 








Table 4. cDNA Master Mix 
 Volume (µL) Final Concentration 
5x cDNA synthesis 
buffer 
4 1x 
dNTP Mix 2 500µM each 
Anchored oligo dT and 
random hexamer mix a 
1  
Verso Enzyme Mix 1  
RT enhancer 1  
Template RNA  5 500ng/5µL 
Nuclease-free water 6  
Total volume 20  
a 3:1 mix of random hexamer and anchored oligo dT 
 
The samples were then placed into the BioRad Real-Time System C1000 
Thermal Cycler Instrument (BioRad, Hercules, CA) for the following cycle (Table 
5). 
 





cDNA samples were purified using the Monarch PRC & DNA Cleanup Kit 
(New England Biolabs, Ipswich, MA) as per the quick protocol for oligonucleotide 
cleanup and then quantified using the Cary 50 spectrophotometer (Agilent, Corp., 
Santa Clara, CA). Briefly, samples were brought up to 50 µl with nuclease-free 
  Temperature  Time  Number of cycles  
cDNA synthesis  42°C 30 min 1 cycle 




water. 100 µl of DNA Cleanup Binding Buffer was added to each 50 µl sample 
after which 300 µl of 200-proof ethanol (Decon Laboratories Inc., King of Prussia, 
PA) was added to each sample. The samples were mixed well by gentle 
pipetting. Samples were loaded onto columns in collection tubes and centrifuged 
at 16 000 x g for 1 minute, the flow-through discarded, and the columns re-
inserted into the collection tubes. Two washed with 500 µL of DNA Wash Buffer 
were performed at 16 000 x g for 1 minute with the flow-through discarded. The 
columns were transferred into clean 1.5 mL microfuge tubes and 10 µl of elution 
buffer placed in the center of the matrix and incubated for 1-2 minute before 
centrifuging at 16 000 x g for 1 minute. An additional 5 µl of elution buffer was 
added to the matrix and incubated for 1-2 minutes before spinning at 16 000 x g 
for 1 minute. The cDNA of the same samples was pooled.  
Total cDNA was analyzed using a full spectrum analysis at 230 nm- 300 
nm in the Cary 50 spectrophotometer (Agilent, Corp., Santa Clara, CA). Total 
cDNA concentrations were calculated using the formula as follows:  
 
Concentration of cDNA= A260 x 33 µg/mL x 10 x dilution factor 
 
Samples of cDNA were stored at -20°C and were diluted to a 50 ng/ 5 µl 




The qRT-PCR experiment was performed using a CFX96 Touch Real-
Time PCR Detection System (BioRad, Des Plaines, IL).  For all experiments, 
reactions were performed in triplicate with Luna Universal qPCR Master Mix 2X 
concentration (New England Biolabs, Ipswich, MA) that contained all necessary 
components to perform a DNA-binding dye base real-time DNA amplification 
experiment. Primers were purchased from Integrated DNA Technologies 
(Coralville, IA) with the sequences, Tm, and base pairs sizes of the products 
shown in Table 6. 
 
Table 6. Primers for qRT-PCR studies 
Genes Primer 
name Primer sequence (5′-3′) 
Size 
(bp) Ref Number 
GAPDH GAPDH For GAGTCCACTGGCGTCTTCA  190 NM_001289746.1 
  GAPDH Rev GGGGTGCTAAGCAGTTGGT    
β-Actin β-Actin For ATCCTCACCCTGAAGTACCC 183 NM_001101.3 
  β-Actin Rev TAGAAGGTGTGGTGCCAGAT   
Caspase 3 Casp3 For AGAACTGGACTGTGGCATTGAG  191 NM_004346.3 
  Casp3 Rev GCTTGTCGGCATACTGTTTCAG   
Caspase 6 Casp6 For ACAGGAGGAGAGGAATTGCT 201 NM_001226.3 
  Casp 6 Rev GGCTAACAGTTGACACCTCATG   
Caspase 7 Casp 7 for2 TCAGTGGATGCTAAGCCAGA 199 NM_001267056.1 
  Casp 7rev2 GAACGCCCATACCTGTCACT   
Caspase 8 Casp8 For GGTCACTTGAACCTTGGGAA 146 NM_001080124.1 
  Casp8 Rev CGGAATGTAGTCCAGGCTCA   
Caspase 9 Casp9 For ACACCCAGACCAGTGGACAT 148 NM_001229.4 
  Casp9 Rev CACGGCAGAAGTTCACATTG   
BCL2 BCL2 For  CAGTTGGGCAACAGAGAACCAT 171 NM_000633.2 





Each reaction mixture contained 10 l of 2X Luna Universal qPCR Master 
Mix, 0.5 l of 10 M forward/reverse primers, 5 l template cDNA (200ng, 100ng, 
50ng, 25ng, 12.5ng, and 6.25ng) and nuclease-free water to a final volume of 20 
l. The 96-well plates were centrifuged at 2500 x g for 4 minutes using the 
Beckman induction drive centrifuge J-6M (Beckman Coulter, Brea, CA). The 
suggested Luna thermal cycling protocol (Table 7) was used for the initial time 
course study.  
 







In order to conduct the efficiency assays duplicated of cDNA dilutions 
were plated in concentrations of 200 ng, 100 ng, 50 ng, 25 ng, 12.5 ng, and 6.25 
ng/well. With the appropriate 0.5 µl forward and reverse primers, 10 µl Luna 
Universal qPCR Master Mix (NEB BioLabs, Ipswich, MA) and 4 µl RNase and 
DNase free water.  
 
Initial denaturation 95°C  1 minutes 
 PCR (45 cycles) 95°C 15 seconds 
60°C 30 seconds 
Melt curve 





The following thermal cycling conditions were used: 
 






The Ct values obtained were exported into Microsoft Excel and the 
logarithm of the initial cDNA template concentration is plotted on the x axis and 
the Ct is plotted on the y axis per primer set (GOI). A standard curve was created 
and the equation and R2 inserted. The slope from the generated equation was 
inserted into the following equation in order to determine the efficiencies.  
 
E=10(-1/slope)-1x100 to determine % efficiency 
 
 Experiments were performed twice in duplicate. Due to the fact that the 
efficiency for BCL2 could not be determined it was dropped from further studies 
and I concentrated on the caspase GOI.  
Initial denaturation 95°C  1 minutes 
 PCR (45 cycles) 95°C 15 seconds 
60°C 30 seconds 
Melt curve 





Quantitative real time polymerase chain reaction assays (qRT-PCR) 
 The structural changes observed by TEM and whole cell staining were 
validated by quantitative real-time polymerase chain reaction (qRT-PCR) assays.  
 Infections, RNA extraction at 6-, 7-, 8-, and 9-hpi, and cDNA synthesis 
were performed as previously described. 50ng of cDNA was used per reaction. 
Plates were run in triplicate as previously described.   
GAPDH and -actin were used as housekeeping genes to normalize for 
relative expression analyses. The cycle threshold (Ct) value or cycle number 
obtained from a single reaction for each standard reaction were all values that fell 
within a linear portion of the standard curve.  The obtained Ct values from the 
qRT-PCR experiment were exported to Microsoft Excel 2016 for data analyses.  
Fold change in signals of expression of the genes of interest relative to GAPDH 
and -Actin were determined by using the Ct method.  The results were 
expressed as mean  SD.   
 
CellTiter 96 AQueous One Solution Cell Proliferation Cell Viability Assay 
 Determining seeding density 
 In order to get accurate readings for the CellTiter 96 AQueous One Solution 
Cell Proliferation Cell Viability Assay (Promega, Madison, WI) readings at 490nm 




SoftMax Pro software (Molecular Devices, Sunnyvale, CA). In order to determine 
what seeding density of cells would give accurate measurements and what 
incubation period to use cells were seeded at 105, 104, 103, 102, and media only 
in triplicate and incubated at 37°C, 5% CO2 for approximately 24 hours. Cells 
were serum starved for 8 hours by replacing the media with DMEM +all without 
FBS media and incubated at 37°C, 5% CO2. Treatments were prepared as 
previously described. Briefly, 25 µL/well of DMEM +all without FBS + 1:1000 WT 
was used for the NV treatments. 25 µL/well of RV treatment made up in DMEM + 
all without FBS + 1:1000 WT having an MOI of 2 was used for the RV treatment. 
DMEM + all without FBS + 1:1000 WT was placed in the blank wells. Treatments 
were left on for an hour as previously described. After an hour the treatment were 
removed and replaced with DMEM + all without FBS + 1:10 000 WT and 
incubated at 37°C, 5% CO2 for 18 hours. At 18 hpi 20 µL of AQueous One Solution 
Reagent was added to each well. The plate was incubated at 37°C, 5% CO2 for 1 
hour protected from light. At the one hour incubation period the plate was 
transferred to the VERSAmax tunable microplate reader (Molecular Devices, 
Sunnyvale, CA) where it was mechanically shaken for 10 seconds before the 490 
nm absorbance was recorded. The data was then blanked using the blank row. 
The cell viability was calculated as follows:  
 




The results from the initial cell seeding experiment were used when 
designing the protocol for the full CellTiter 96 AQueous One Solution Cell 
Proliferation Cell Viability Assay and APO 3/7 assay.   
 
CellTiter 96 AQueous One Solution Cell Proliferation Cell Viability Assay 
Viability assays were performed with RV alone, RV with 20 µM A3 or sA3, 
20 µM A3 or sA3 alone, and cells without treatment (NV) using the CellTiter 96 
AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI). Briefly, 
cells were seeded at a density of 104 in 96 well plates (Evergreen Scientific, Los 
Angeles, CA). Approximately 24-hours after plating the cells were serum starved 
for 8 hours by replacing the media with DMEM + all without FBS media and 
incubated at 37°C, 5% CO2. Treatments prepared as described in the RV 
Infection section were performed. Briefly, Wa RV stock was sonicated 10 min 
using a cup horn attachment and ice bath in a Misonix Sonicator 3000 (Misonix, 
Inc., Farmingdale, NY) and incubated in serum-free DMEM with 10 μg/mL trypsin 
(WT) for 45 min at 37°C. The activated viral inoculum was incubated with the 
cells for 1 hour at 37°C in 5% CO2 at an MOI of 2. After which the treatments 
were removed and DMEM + all without FBS + 1:10 000 WT was placed on the 
cells (100 µl/well) and incubated for 12-18 hours at 37°C, 5% CO2. At 12-, 14-, 
16-, and 18hpi 20 µl of the CellTiter 96 AQueous One Solution Reagent was added 




plates were incubated at 37°C, 5% CO2 for 1 hour protected from light. After the 
incubation time the plates were read on the VERSAmax tunable microplate reader 
and SoftMax Pro software (Molecular Devices, Sunnyvale, CA). The plates were 
shaken for 10 seconds and then the absorbance at 490 nm was recorded. Cell 
viability was calculated by blanking data against the blank well (media + AQueous 
One Solution Reagent). The blanked data was then used to calculate the cell 
viability using the following formula:  
 
Treatment 490nm absorbance/NV 490nm absorbance x 100 = % cell viability 
 
Each treatment was performed in triplicate and experiments were 
repeated three times. Data were statistically analyzed in Microsoft Office Excel 
2016 software using one-way analysis of variance (ANOVA) and two-tailed 
Student’s t tests (significance level, P <0.05) with Bonferroni’s post hoc test to 
correct for multiple comparisons (P <0.005). 
 
Apo-ONE Homogeneous Caspase-3/7 Assay  
Apo-ONE Homogeneous Caspase-3/7 assays were carried out at 12-, 14-, 
16-, and 18-hpi using the Apo-ONE Homogeneous Caspase-3/7 Assay 
(Promega, Madison, WI). Briefly, HT29.f8 cells were plated in 96-well tissue 




time point at 104 cells/well and incubated at 37°C, 5% CO2 for 24 hours. The cells 
were then serum starved overnight by replacing media with DMEM + all without 
FBS. The cells were infected as previously described and accounting for blanks 
and negative controls. After treatment 100 µl of DMEM + all without FBS + 1:10 
000 WT was placed in each well. At the 12-, 14-, 16-, and 18-hpi time points the 
media was removed and replaced with 25 µl/well of fresh DMEM + all without 
FBS media. 25 µl of Apo-ONE Caspase-3/7 Reagent was added to each well and 
the plates shaken for 15 minutes using the Bio-Rad iMark Microplate Reader 
(Bio-Rad, Hercules, CA) and then kept in the dark at room temperature for a 
further 45 minutes. The contents of the wells were then transferred to a 
microplate 96 well black plate (Greiner bio-one, 655096) (Greiner bio-one Inc., 
Denver, CO). The contents of the wells were gently spun down at 2500 rpm 
using the Beckman Coulter Avanti J-15R centrifuge (Beckman Coulter, Brea, 
CA).  
Fluorescence was measured at 499nm using the Typhoon FLA 9000 (GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden) and determined empirically. 
 Caspase-3/7 activity was calculated as follows: 
 
Assay RFU-Blank RFU 




The percent cell viability for each treatment obtained from the AQeous One assay 
was used to further correct the data. 
 
Data were statistically analyzed in Microsoft Office Excel 2016 software 
using one-way analysis of variance (ANOVA) and two-tailed Student’s t tests 
(significance level, P <0.05) with Bonferroni’s post hoc test to correct for multiple 

























Mycoplasma Detection  
The PCR Mycoplasma Test Kit I/C from PromoKine was used to detect 
over seven species of Mycoplasma. The positive control shows a distinct band at 
265-278bp which represents a highly conserved 16S rRNA operon region in the 
Mycoplasma genome. The negative internal control and both samples only 
showed a band at 479bp indicating that the amplification process was successful 








Figure 1. PCR Mycoplasma testing in HT29.f8 and MA104 cell lines. PCR 
products from the PCR Mycoplasma Test Kit I/C and the Apex 100 bp-Mid DNA 
marker (Genesee Scientific, San Diego, CA) were run on a 1.5% agarose gel, 
and visualized on the Typhoon FLA 9000 (GE Healthcare Life Sciences, 
Pittsburgh, PA). The positive control shows a distinct band at 265-278 bp. The 
internal control band was present in all samples at 479bp indicating that the PCR 




















































































Toxicity of A3 and sA3 on HT29.f8 cells  
Percent live/dead cells were calculated using the trypan blue exclusion 
dye assay as previously described (Ball et al., 2015).  At 18hpi, the cells treated 
with NV, A3, and sA3 had cell viabilities of 93.5% ±1.73, 95.25% ±2.50, and 
93.75% ±2.06, respectively. Cells infected with RV alone had a viability of 
90.75% ±2.06 and cells with RV and 0.02% DMSO had a viability of 91.25% 
±1.89. RV-infected cells treated with the A3 and sA3 showed an increased 
viability of 94.75% ±2.22 and 92.50% ±1.25, respectively (Fig. 2). Therefore, the 





Figure 2. HT29.f8 cell viability assay at 18hpi using a trypan blue exclusion dye 
assay. Cells were counted in quadruplicate for each treatment at 18hpi and 
percent live/dead cells were calculated. Data were statistically analyzed in 
Microsoft Office Excel 2016 software using a one-way analysis of variance 
(ANOVA) and a two-tailed Student’s t tests (significance level, P <0.05) with 










Production of infectious RV with the addition of A3 and sA3 
Supernatants collected at 18hpi from the RV-infected and RV-infected with 
20 µM concentrations of A3 or sA3 were used for plaque forming assays to 
quantify the amount of infectious viral progeny produced (Arnold et al., 2009).  
The PFU assays demonstrated statistically significant differences between RV 
and RV+A3 (P = 0.0075) and RV and RV+sA3 (P = 0.0075); representing 48-fold 
change decrease in PFU with A3 treatment and a 51-fold change decrease in 






Figure 3. Quantification of infectious Wa RV particles using plaque forming 
assays (PFU/mL) at 18 hpi. HT29.f8 cells were infected with RV, RV+20 µM A3, 
or RV +20 µM sA3.  At 18 hpi, the supernatants were collected, clarified by 
centrifugation, and used in plaque forming assays. The RV titer was 3.66E11, RV 
with A3 titer was 7.67E09, and RV with A3 titer was 7.17E09. Experiments were 
conducted in triplicate during four different experiments.  *Comparison of RV only 

























PFU/mL for HT29.f8 cells with/without 
arachidin treatments  
7.67E+09 7.17E+09 
RV                      RV+A3                   RV+sA3 





Quantification of nanoparticles and size distribution by TRPS 
analysis 
The concentrations and diameters of nanoparticles (~50-150 nm) were 
measured using the Izon qNano system at 16 and 18hpi. Figure 4 are the 
resultant images created from one representative run in the IZON proprietary 
software v3.2.2.268 (Izon). RV-only samples showed the concentration of 
1.71E13 and 2.13E13 particles/mL at 16 and 18hpi, respectively (Fig. 4A), and 
the average particle populations’ diameter was 79 nm and 74 nm at 16 and 18hpi 
(Fig. 4A). RV-infected cells treated with A3 demonstrated a nanoparticle 
concentration of 1.71E13 and 2.01E13 particles/mL at 16 and 18hpi, respectively 
(Fig. 4B). However, the RV-infected cell treated with A3 demonstrated 
nanoparticle diameter averaged 97 nm at 16 hpi that shifted to a population of 
larger particles (116 nm) particles at 18hpi (Fig. 4B). Likewise, RV-infected cells 
treated with sA3 demonstrated a nanoparticle concentration of 2.01E13 and 
2.10E13 particles/mL at 16 and 18hpi, respectively (Fig. 4C). With sA3 treatment 
16hpi nanoparticle sizes were averaging 95 nm; however, at 18hpi a shift to a 
population of larger particles (117 nm) was revealed (Fig. 4C).  
Data from triplicate runs at 16 and 18hpi were statistically analyzed in 
Microsoft Office Excel 2016 software using a one-way analysis of variance 




Bonferroni’s post hoc test to correct for multiple comparisons (P <0.017) is shown 
in table 9. At both the 16 and 18hpi time points there was a statistical difference 
in the mean nanoparticle diameter of the RV and RV with the addition of either of 
the arachadins (A3 or sA3). (16hpi: RV/RV+A3 (P= 0.000133986), RV/RV+sA3 








Figure 4. Overlaid tunable resistant pulse sensing technology (TRPS) analyses 
of nanoparticles/mL released from RV-infected and RV-infected-arachidin treated 
HT29.f8 cells at 16 and 18hpi. 4A (RED  ) RV only 16 
and 18hpi particles/mL= 1.71E13 and 2.13E13 respectively, mean diameter 
(nm)= 79 and 74 respectively, and N= 426 and 387 respectively. 4B (BLUE
) RV+A3 16 and 18hpi particles/mL= 1.71E13 and 
2.01E13 respectively, mean diameter (nm)= 97 and 116 respectively, and N= 
480 and 344 respectively. 4C (GREEN ) RV+sA3 16 and 
18hpi particles/mL= 1.68E13 and 2.10E13 respectively, mean diameter (nm)= 95 




























Table 9. Statistical analysis of triplicate TRPS runs 
 
a-d Data from triplicate runs at 16 and 18hpi were statistically analyzed in 
Microsoft Office Excel 2016 software using a one-way analysis of variance 
(ANOVA) and a two-tailed Student’s t tests (significance level, P <0.05) with 
Bonferroni’s post hoc test to correct for multiple comparisons (P <0.017) is shown 
in table 9. At both the 16 and 18hpi time points there was a statistical difference 
in the mean nanoparticle diameter of the RV and RV with the addition of either of 
the arachadins. (16hpi: aRV/RV+A3 (P= 0.000133986), bRV/RV+sA3 (P= 









TEM and whole cell fluorescent analyses of nucleus to cytoplasm ratios of 
HT29.f8 cells  
TEM and fluorescent analysis was performed on HT29.f8 cells infected 
with RV, RV with A3, and RV with sA3.  These were compared to the three 
controls, NV, A3, and sA3. TEM analysis was performed at 16 and 18hpi and 
fluorescent analysis was performed at 18hpi (Fig 5, 6, and 7).  
TEM analysis revealed that at 16 hpi, the mean ratio of RV-infected cells 
was 0.87 ±0.51, showing an increase in comparison to the control cells (NV, 
A1and A3 alone) as shown in figure 5.  At the same time point, RV-infected cells 
treated with A3 had a smaller average nucleus/cytoplasm ratio of 0.41 ±0.19 at 
16hpi (Fig. 5). RV+sA3 cells had an average nucleus/cytoplasm ratio of 0.51 






Figure 5. 16hpi HT29.f8 TEM nucleus/cytoplasm ratios. Data expressed at mean 
±SD, N= 10. RV only, RV+A3, and RV+sA3 representative cells along top. 
Representative cells of the controls NV, A3, and sA3 to the side. Scale bars = 
2µm. Data were statistically analyzed in Microsoft Office Excel 2016 software 
using a one-way analysis of variance (ANOVA) (significance level, P <0.05). No 
statistical difference between groups was detected. The data was graphed using 
a whisker and box plots.  The box represents all the data points within the lower 
(Q1) and upper (Q3) quartiles with vertical lines with an x that represents the 
median. The whiskers go from each quartile to the minimum and maximum data 
points. Data points falling outside the overall pattern of distribution were plotted 









At 18 hpi, the ultrastructural appearance and mean nuclear to cytoplasm 
ratios of the control cells with A3 (0.50 ±0.15) and sA3 (0.47 ±0.09) were similar 
to the cells with no treatment (0.46 ±0.15) (Fig. 6). An increase in the number of 
mitochondria, autophagosomes, RV particles and viroplasms was demonstrated 
in RV-infected cells, and RV-infected cells. At 18 hpi, the RV-infected cells 
demonstrated an increased nucleus to cytoplasm ratio of 1.18 ±0.34 while RV-
infected cells treated with either arachidin had similar mean ratios, 0.42 ±0.17 
and 0.65 ±0.25, respectively, and both A3 or sA3 treatments showed relatively 
normal ultrastructure (Fig. 6). RV was statistically different from NV (P= 9.23E-







Figure 6. 18hpi HT29.f8 TEM nucleus/cytoplasm ratios. Data expressed as mean 
±SD, N= 10. RV only, RV+A3, and RV+sA3 representative cells along top. 
Representative cells of the controls NV, A3, and sA3 to the side. Scale bars = 
2µm. Data were statistically analyzed in Microsoft Office Excel 2016 software 
using a one-way analysis of variance (ANOVA) and a two-tailed Student’s t tests 
(significance level, P <0.05) with Bonferroni’s post hoc test to correct for multiple 
comparisons (P <0.0033). The data was graphed using whisker and box plots.  
The box represents all the data points within the lower (Q1) and upper (Q3) 
quartiles with vertical lines with an x that represents the median.  The whiskers 
go from each quartile to the minimum and maximum data points. Data points 
falling outside the overall pattern of distribution were plotted as dots that 
represent outliers. RV was statistically different from NV (P= 9.23E-06); RV+A3 






At 18 hpi whole cell staining was used to verify the TEM results (Fig. 7). 
The nucleus/cytoplasm ratios obtained from the live staining supports the TEM 
data. Although exact ratios where slightly different the general trends remained 
the same. Nucleus/cytoplasm ratios at 18hpi were as follows: RV= 1.04 ±0.63, 
RV+A3= 0.61 ±0.24, RV+sA3= 0.53 ±0.2, NV= 0.67 ±0.26, A3 only= 0.58 ±0.19, 
and sA3 only= 0.51 ±0.13. RV was statistically different from NV (P= 0.00041); 
RV+A3 (P=2.1E-05); RV+sA3 (P= 3.6E-07); A3 only (P= 2.7E-06); and sA3 (P= 






Figure 7. 18hpi whole cell staining nucleus/cytoplasm (N/C) ratios. Data 
expressed as mean ±SD.N/C ratios of 50 cells per treatment were averaged and 
statistically analyzed using Microsoft Office Excel 2016 software using a one-way 
analysis of variance (ANOVA) and a two-tailed Student’s t tests (significance 
level, P <0.05) with Bonferroni’s post hoc test to correct for multiple comparisons 
(P <0.0033). The data was graphed using whisker and box plots.  The box 
represents all the data points within the lower (Q1) and upper (Q3) quartiles with 
vertical lines with an x that represents the median.  The whiskers go from each 
quartile to the minimum and maximum data points. Data points falling outside the 
overall pattern of distribution were plotted as dots that represent outliers. 
Averages were as follows: RV= 1.04 ±0.63 RV+A3= 0.61 ±0.24, RV+sA3= 0.53 
±0.2, NV= 0.67 ±0.26, A3 only= 0.58 ±0.19, and sA3 only= 0.51 ±0.13. RV was 
statistically different from NV (P= 0.00041); RV+A3 (P=2.1E-05); RV+sA3 (P= 
3.6E-07); A3 only (P= 2.7E-06); and sA3 (P= 1.3E-07). NV was statistically 




Quantification of transcripts for cell death pathway genes in HT29.f8 
cells 
 QuantiFluor dsDNA assay 
The QuantiFluor dsDNA assay was conducted to assure pipetting and 
plating accuracy. Table 10 and figure 8 show the representative data for the 
dsDNA Standard Curve and QuantiFluor dsDNA Dye while Table 11 shows the 
unknown dilutions and average fluorescence.  
 
Table 10. Representative Data for the dsDNA Standard Curve and QuantiFluor 
dsDNA dye 











The data from the QuantiFluor was graphed and the standard curve was 
created using Microsoft Office Excel 2016 software (Figure 8). The generated 
equation of y= 608459x+92471 (x=(y-92471)/608459) was used to determine the 
original concentrations of the diluted unknown sample that were performed in 
triplicate.  
Figure 8. Standard curve plotted using the fluorescence (rfu) and lambda DNA 
(ng/well) values. The equation generated was used to calculate the unknown 





The R2 value was 0.9995. Table 11 shows the calculated concentrations. 
The unknown concentration was determined to be between 7.14 ng/µl-8.3ng/µl.   
 
Table 11. Sample Dilution Series and QuantiFluor dsDNA dye of lambda DNA  




1/10 4434040 7.14  
1/100 548533.2 7.5 
1/1000 143109.2 8.3 
























 Efficiency assays were performed twice in duplicate on the GOI primers. 
The housekeeping and caspase primers showed efficiencies ranging from 92.55-
110.52%. BCL2 efficiency could not be calculated and therefore it was decided to 
drop BCL2 and the other Autophagy GOI from this study and concentrate on the 
caspase GOI.  
 
Primer Calculated % efficiency  
GAPDH 92.55 
𝛃-actin 110.52 
CASP 3 105.44 
CASP 6 105.31 
CASP 7.2 103.0 
CASP 8 103.75 
CASP 9 105.65 
BCL 2  
Table 12. PCR efficiencies calculated from two duplicate run efficiency assays. 






Figure 9. Calculated efficiencies for GOI primers from two efficiency assays run 






GAPDH β-actin CASP 3 CASP 6
CASP
7.2
CASP 8 CASP 9 BCL 2
Efficiency (%) 92.55 110.52 105.44 105.31 103.00 103.75 105.65































 To determine if the arachidins regulated the transcripts of genes that 
encoded for proteins that initiated either the apoptosis or autophagy pathways, 
qRT-PCR experiments were performed on arachidin treated RV-infected HT29.f8 
cells at 6, 7, 8, and 9hpi (Figure 10-18).   
At 6hpi (figure 10) there appears to be a slight upregulation of caspase 3, 
6, 7, and 8 with sA3 alone (1.19 ±0.11, 1.33 ±0.09, 1.28 ±0.07, and 1.37 ±0.05 
respectively). The other treatments appear to cause slight down or no regulation 
of caspase 3, 6, 7, and 8. All the treatments had little or no effect on the 
regulation of caspase 9.  
At 7hpi (figure 11) caspase 3 is not regulated by RV, RV+A3, or RV+sA3 
while it is slightly upregulated by A3 and sA3 (1.55 ±0.11, and 1.20 ±0.06 
respectively). Caspase 6 is slightly upregulated by all the treatments (RV 1.15 
±0.03, RV+A3 1.29 ±0.05, RV+sA3 1.02 ±0.11, 1.31 ±0.06, and 1.32 ±0.07). 
Caspase 7 is slightly upregulated by all the treatments (RV 1.18 ±0.09, RV+A3 
1.33 ±0.08, RV+sA3 1.07 ±0.08, A3 1.20 ±0.06, and sA3 1.21 ±0.07). RV, 
RV+A3, and RV+sA3 cause slight down regulation of caspase 8 (0.85 ±0.05, 
0.79 ±0.03, and 0.9 ±0.07 respectively) while A3 and sA3 alone cause slight 
upregulation of caspase 8 (1.17 ±0.1, and 1.21 ±0.05). RV, RV+A3, and RV+sA3 




±0.1) while A3and sA3 cause the slight to no regulation of caspase 9 (1.15 ±0.1, 
and 0.99 ±0.07).  
At 8hpi (figure 12) caspase 3 is down regulated by all the treatments (RV 
0.63 ±0.04, RV+A3 0.69 ±0.05, RV+sA3 0.52 ±0.03, A3 0.9 ±0.08, and sA3 0.39 
±0.03). RV, RV+sA3, and sA3 downregulate caspase 6 (0.79 ±0.03, 0.82 ±0.13, 
and 0.84 ±0.08 respectively) while RV+A3 and A3 upregulate caspase 6 (1.28 
±0.05 and 1.44 ±0.08 respectively). Caspase 7 is downregulated by both RV and 
sA3 (0.88 ±0.04, and 0.86 ±0.08 respectively) while RV+A3, RV+sA3, and A3 all 
slightly upregulate caspase 7 (1.27 ±0.09, 1.13 ±0.06, and 1.17 ±0.12 
respectively). Caspase 8 is slightly downregulated by RV, RV+sA3, and sA3 
(0.92 ±0.08, 0.85 ±0.09, and 0.98 ±0.1) and slightly upregulated by RV+A3 and 
A3 (1.14 ±0.05 and 1.05 ±0.09). RV, RV+A3, RV+sA3 and A3 slightly 
downregulate caspase 9 (0.8 ±0.04, 0.93 ±0.04, 0.8 ±0.06 and 0.97 ±0.06) while 
sA3 slightly upregulates caspase 9 (1.01 ±0.09).   
At 9 hpi (figure 13) all treatments downregulated caspase 3 (RV 0.67 
±0.06, RV+A3 0.72 ±0.05, RV+sA3 0.54 ±0.03, A3 0.94 ±0.08, and sA3 0.4 
±0.03). RV, RV+sA3, and sA3 downregulated caspase 6 (0.8 ±0.03, 0.84 ±0.13, 
and 0.85 ±0.09 respectively) while RV+A3 and A3 slightly upregulated caspase 6 
(1.32 ±0.04 and 1.16 ±0.09 respectively). RV and sA3 downregulated caspase 7 




upregulated caspase 7 (1.29 ±0.1, 1.17 ±0.06, and 1.21 ±0.12 respectively). RV, 
A3, and sA3 slightly downregulated caspase 8 (0.89 ±0.12, 0.83 ±0.09, and 0.96 
±0.1 respectively) while RV+A3 and RV+sA3 slightly upregulated caspase 8 
(1.13 ±0.04 and 1.03 ±0.08). All treatments slightly downregulated or did not 
regulate caspase 9 (RV 0.77 ±0.04, RV+A3 0.9 ±0.03, RV+sA3 0.8 ±0.06, A3 
0.97 ±0.06, and sA3 1.01 ±0.09).  
Figure 14 shows a time course of caspase 3 regulation with the various 
treatments. At appears that RV, RV+A3, and RV+sA3 have a similar time course 
pattern (slight down regulation at 6hpi, less downregulated at 7hpi, down 
regulated at 8 and 9hpi. A3 and sA3 show a similar time course pattern; both 
being upregulated at 6 and 7hpi and downregulated at 8 and 9 hpi. This time 
course study suggests that 7-8hpi is of particular importance in terms of changes 
in this system.  
Figure 15 shows a time course of caspase 6 regulation with the various 
treatments. RV switches from upregulating caspase 6 at 6 and 7hpi to 
downregulating caspase 6 during 7 and 8hpi. Again showing 7-8hpi being an 
important time point in terms of changes. RV+A3 initially downregulates caspase 
6 and 6hpi but then upregulates it during 7, 8, and 9hpi. RV+sA3 showed a 
different pattern; downregulating caspase 6 at 6hpi, showing very little regulation 




showed different time course patterns. At 6hpi A3 downregulated caspase 6 but 
at 7, 8, and 9hpi A3 upregulates caspase 6. sA3 upregulated caspase 6 at 6 and 
7hpi but then downregulated caspase 6 at 7 and 8hpi.   
Figure 16 shows a time course of caspase 7 regulation with the various 
treatments. RV slightly upregulated caspase 7 at 6 and 7hpi and then 
downregulated caspase 7 at 8 and 9hpi; again showing 7-8hpi being an 
important time point in terms of changes. Both RV+A3 and RV+sA3 slightly down 
regulated caspase 7 and 6 hpi but then slightly upregulated caspase 7 at 7, 8, 
and 9hpi. A3 and sA3 showed different time course patterns. A3 down regulated 
caspase 7 at 6 hpi but then upregulated caspase 7 at 7, 8, and 9hpi while sA3 
slightly upregulated caspase 7 at 6 and 7hpi and then down regulated caspase 7 
at 8 and 9hpi.  
Figure 17 shows a time course of caspase 8 regulation with the various 
treatments. The time course patterns for the various treatments showed variable 
time course patterns for caspase 8. RV initially slightly upregulated caspase 8 at 
6hpi and then slightly down regulated caspase 8 at 7, 8, and 9hpi. RV+A3 slightly 
upregulated caspase 8 at 6hpi, then down regulated caspase 8 at 7hpi, and then 
slightly upregulated caspase 8 at both 8 and 9hpi. RV+sA3 slightly 
downregulated caspase 8 at 6, 7, and 8hpi and then ever so slightly upregulated 




slightly downregulated caspase 8 at 9hpi. sA3 slightly upregulated caspase 8 at 6 
and 7hpi and then slightly down regulated caspase 8 at 8 and 9hpi.  
Figure 18 shows a time course of caspase 9 regulation with the various 
treatments. RV, RV+A3, and RV+sA3 all slightly downregulated caspase 9 over 
all the time points investigated (6, 7, 8, and 9hpi). A3 initially slightly upregulated 
caspase 9 at 6 and 7hpi ad then slightly downregulated/ did not regulate caspase 
9 at 8 and 9hpi. sA3 initially slightly upregulated caspase 9 at 6hpi and then did 
not regulate/ ever so slightly down regulated caspase 9 at 7, 8, and 9hpi.  
Many of the up and down regulations noted where very slight. However, 













Figure 10. Changes in gene transcription in HT29.f8 cells 6hpi. Fold change in 
signals of expression of GOI relative to GAPDH and β-actin were determined 
using the ∆∆CT method. The results are expressed as mean ±SD. Experiments 









































Figure 11. Changes in gene transcription in HT29.f8 cells 7hpi. Fold change in 
signals of expression of GOI relative to GAPDH and β-actin were determined 
using the ∆∆CT method. The results are expressed as mean ±SD. Experiments 











































Figure 12. Changes in gene transcription in HT29.f8 cells 8hpi. Fold change in 
signals of expression of GOI relative to GAPDH and β-actin were determined 
using the ∆∆CT method. The results are expressed as mean ±SD. Experiments 











































Figure 13. Changes in gene transcription in HT29.f8 cells 9hpi. Fold change in 
signals of expression of GOI relative to GAPDH and β-actin were determined 
using the ∆∆CT method. The results are expressed as mean ±SD. Experiments 












































Figure 14. Changes in caspase 3 gene expression in HT29.f8 cells 6-9hpi. Fold 
change in signals of expression of GOI relative to GAPDH and β-actin were 
determined using the ∆∆CT method. The results are expressed as mean ±SD. 








































Figure 15. Changes in caspase 6 gene expression in HT29.f8 cells 6-9hpi. Fold 
change in signals of expression of GOI relative to GAPDH and β-actin were 
determined using the ∆∆CT method. The results are expressed as mean ±SD. 








































Figure 16. Changes in caspase 7 gene expression in HT29.f8 cells 6-9hpi. Fold 
change in signals of expression of GOI relative to GAPDH and β-actin were 
determined using the ∆∆CT method. The results are expressed as mean ±SD. 





































Figure 17. Changes in caspase 8 gene expression in HT29.f8 cells 6-9hpi. Fold 
change in signals of expression of GOI relative to GAPDH and β-actin were 
determined using the ∆∆CT method. The results are expressed as mean ±SD. 








































Figure 18. Changes in caspase 9 gene expression in HT29.f8 cells 6-9hpi. Fold 
change in signals of expression of GOI relative to GAPDH and β-actin were 
determined using the ∆∆CT method. The results are expressed as mean ±SD. 













































AQueous One Solution Cell Proliferation Assay 
 In order to get accurate readings in the CellTiter 96 AQueous One Solution 
Cell Proliferation Assay cell seeding density had to be determined in order to 
obtain 490nm absorbance values below one. During the cell seeding 
experiments (Fig. 19) 104 cells/well was determined to be the ideal seeding 
density for future experiments as 105 cells/well gave readings above 1abs at 
490nm wavelength whilst seeding densities below 104 did not give consistent 
readings. 
 
Figure 19. Absorbance at 490nm was noted for cells seeded in triplicate at 105, 
104, 103, and 102 cells/well at 18hpi with NV and RV treatments. 104 cells/well 
was determined to be the ideal seeding density for future CellTiter 96 AQueous 






























Cell seeding density and treatment  










 The CellTiter 96 AQueous One Solution Cell Proliferation Assay was 
performed in triplicate three times for 12-18hpi and resulted in cell viabilities 
ranging from 65.37-80.69% at 18hpi (Fig. 24). At 12hpi (Fig. 20) RV cell viability 
was 88.46 ±1.90%, RV+A3 was 90.14 ±3.54%, RV+sA3 was 91.37 ±5.48%, A3 
was 93.98 ±3.04%, and sA3 was 89.79 ±4.47%. At 12hpi RV treatment cell 
viability is only slightly lower than the other treatments with no statistically 
significant differences being noted.  
 
Figure 20. CellTiter 96 AQueous One Solution Cell Proliferation Assay results at 
12hpi for each treatment. Experiments were conducted three times in triplicate. 
Data were statistically analyzed in Microsoft Office Excel 2016 software using a 
one-way analysis of variance (ANOVA) and a two-tailed Student’s t tests 
(significance level, P <0.05) with Bonferroni’s post hoc test to correct for multiple 




 At 14hpi cell viability (Fig. 21) for each treatment decreased from the 
12hpi viabilities. RV treatment cell viability was 75.89 ±3.75%, RV+A3 was 83.93 
±5.52%, RV+sA3 was 85.08 ±0.62%, A3 was 87.85 ±3.49%, and sA3 was 87.99 
±4.56%. The RV treatment cell viability was statistically different from each 
treatment with P values of 0.002, 1.79E-06, 2.8E-06, and 1.3E-05 respectively.  
 
Figure 21. CellTiter 96 AQueous One Solution Cell Proliferation Assay results at 
14hpi for each treatment. Experiments were conducted three times in triplicate. 
Data were statistically analyzed in Microsoft Office Excel 2016 software using a 
one-way analysis of variance (ANOVA) and a two-tailed Student’s t tests 
(significance level, P <0.05) with Bonferroni’s post hoc test to correct for multiple 
comparisons (P <0.005). RV was statistically different from RV+A3 (P= 0.002); 





 At 16hpi the cell viabilities were further decreased (Fig. 22). RV treatment 
cell viability was 69.96 ±0.39%, RV+A3 was 77.55 ±6.79%, RV+sA3 was 78.20 
±4.34%, A3 was 86.02 ±6.30%, and sA3 was 86.61 ±6.93%. RV treatment cell 
viability was statistically different from each of the other treatments with P values 
of 0.004, 3.24E-05, 9.77E-07, and 2.07E-06 respectively.  
 
Figure 22. CellTiter 96 AQueous One Solution Cell Proliferation Assay results at 
16hpi for each treatment. Experiments were conducted three times in triplicate. 
Data were statistically analyzed in Microsoft Office Excel 2016 software using a 
one-way analysis of variance (ANOVA) and a two-tailed Student’s t tests 
(significance level, P <0.05) with Bonferroni’s post hoc test to correct for multiple 
comparisons (P <0.005). RV was statistically different from RV+ A3 (P= 0.0038); 




At 18hpi the cell viabilities were further decreased (Fig. 23). RV treatment 
cell viability was 64.64 ±3.56%, RV+A3 was 76.18 ±4.53%, RV+sA3 was 76.20 
±2.21%, A3 was 83.60 ±6.50%, and sA3 was 81.99 ±2.93%. RV treatment cell 
viability was statistically different from each of the other treatments with P values 
of 1.75E-05, 3.3E-07, 9.2E-07, and 4.8E-09 respectively. RV+A3 was just 
statistically different from A3 with a P value of 0.00494. RV+sA3 was just 







Figure 23. CellTiter 96 AQueous One Solution Cell Proliferation Assay results at 
18hpi for each treatment. Experiments were conducted three times in triplicate. 
Data were statistically analyzed in Microsoft Office Excel 2016 software using a 
one-way analysis of variance (ANOVA) and a two-tailed Student’s t tests 
(significance level, P <0.05) with Bonferroni’s post hoc test to correct for multiple 
comparisons (P <0.005). RV was statistically RV+A3 (P= 1.75E-05); RV+sA3 (P= 
3.3E-07); A3 (P= 9.2E-07); and sA3 (P= 4.8E-09). RV+A3 was statistically 








 Data showing cell viability for each treatment over the 12-18hpi 
time points (Fig. 24) demonstrates the increased rate of decreased cell 
viability in the RV treated cells compared to RV+A3/sA3 or A3/sA3 alone. 
This suggests that A3 and sA3 may be conveying a protective effect to 
the cells both when introduced to RV infections as well as by themselves.  
 
Figure 24. CellTiter 96 AQueous One Solution Cell Proliferation Assay results at 
12-18hpi for each treatment. Experiments were conducted three times in 





 Caspase 3 and 7 are involved in the apoptosis process and are known to 
be executioner caspases. The Apo-ONE Homogeneous Caspase-3/7 Assay from 
Promega was used to investigate the caspase-3/7 activity in HT29.f8 cells with 
the various treatments. Caspase-3/7 activity was elevated in all treatments at 
12hpi. RV only treatments had a sharp drop in caspase-3/7 expression at 14hpi 
after which it increased again. RV+A3 and RV+sA3 treatments dropped in 
expression at 14hpi, had slight increases at 16hpi, but significant decreases by 
18hpi. A3 and sA3 alone dropped in expression at 14, and 16hpi and started 







Figure 25. Fold changes in the caspase-3/7 activity observed from NV treated 
HT29.f8 cells vs. treated cells at 12hpi using the APO3/7 assay. Data shown as 
mean ±SD. Experiments performed in triplicate three times. Data were 
statistically analyzed in Microsoft Office Excel 2016 software using a one-way 
analysis of variance (ANOVA) and a two-tailed Student’s t tests (significance 
level, P <0.05) with Bonferroni’s post hoc test to correct for multiple comparisons 
(P <0.005). RV was statistically different from RV+A3 (P= 1.22E-05); RV+sA3 
(P=1.39E-05); A3 (P=1.33E-13); and sA3 (P= 2.64E-13). RV+A3 was statistically 
different from A3 (P= 6.99E-17); and sA3 (P= 1.59E-16). RV+sA3 was 






Figure 26. Fold changes in the caspase-3/7 activity observed from NV treated 
HT29.f8 cells vs. treated cells at 14hpi using the APO3/7 assay. Data shown as 
mean ±SD. Experiments performed in triplicate three times. Data were 
statistically analyzed in Microsoft Office Excel 2016 software using a one-way 
analysis of variance (ANOVA) and a two-tailed Student’s t tests (significance 
level, P <0.05) with Bonferroni’s post hoc test to correct for multiple comparisons 
(P <0.005). RV was statistically different from RV+A3 (P= 0.000621); and sA3 







Figure 27. Fold changes in the caspase-3/7 activity observed from NV treated 
HT29.f8 cells vs. treated cells at 16hpi using the APO3/7 assay. Data shown as 
mean ±SD. Experiments performed in triplicate three times. . Data were 
statistically analyzed in Microsoft Office Excel 2016 software using a one-way 
analysis of variance (ANOVA) and a two-tailed Student’s t tests (significance 
level, P <0.05) with Bonferroni’s post hoc test to correct for multiple comparisons 
(P <0.005). RV was statistically different from A3 (P= 2.02E-07); sA3 (P= 1.78E-
09). RV+A3 was statistically different from A3 (P= 3.07E-05); and sA3 (P= 1.41E-













Figure 28. Fold changes in the caspase-3/7 activity observed from NV treated 
HT29.f8 cells vs. treated cells at 18hpi using the APO3/7 assay. Data shown as 
mean ±SD. Experiments performed in triplicate three times. Data shown as mean 
±SD. Experiments performed in triplicate three times. Data were statistically 
analyzed in Microsoft Office Excel 2016 software using a one-way analysis of 
variance (ANOVA) and a two-tailed Student’s t tests (significance level, P <0.05) 
with Bonferroni’s post hoc test to correct for multiple comparisons (P <0.005). RV 
was statistically different from RV+A3 (P= 0.000364); RV+sA3 (P= 2.38E-10); 
and A3 (P= 1.31E-11). RV+A3 was statistically different from RV+sA3 (P= 1.94E-
05); A3 (P= 9.71E-12); and sA3 (P= 0.001146). RV+sA3 was statistically different 
from A3 (P= 4.7E-16); and sA3 (P=4.52E-09). A3 was statistically different from 






Figure 29. Fold changes in the caspase-3/7 activity observed from NV treated 
HT29.f8 cells vs. treated cells at 12-18hpi using the APO3/7 assay. Data shown 





























































Previous experiments using the simian RV, SA11.4f, revealed antiviral 
effects of both A1 and A3 that reduced the amount of released infectious RV and 
a reduction in NSP4 suggested a decrease in viral replication (Ball et al., 2015). 
This study investigated the effects of A3 and sA3 on the clonally derived human 
intestinal cell line, HT29.f8, infected with the human RV strain, Wa.  Time course 
experiments (16 and 18 hpi) were performed to observe the intracellular patterns 
of the host cell and production of RV particles in RV-infected cells with/without 
the arachidins.  At the same time points, extracellular nanoparticles were counted 
and measured to determine the diameter size of the populations. 
 Trypan Blue Cell Viability assay data showed no statistical difference 
between all groups tested compared to NV. This implies that the arachidins were 
not toxic to the host cells at 20µM concentrations (Fig. 2). Therefore, any effects 
observed in this study can be attributed to the mechanism of action of the 
arachidins.  
PFU assays are commonly used to determine titers (PFU/mL) for 
infectious virus particles (Arnold et al., 2012).  Previously, we reported a 




simian RV, SA11.4f (Ball et al., 2015).  This is the first report to demonstrate that 
the human RV (Wa)-infected cells treated with A3 and sA3 produced significantly 
fewer infectious RV particles than untreated RV-infected cells (Fig.3). Suggesting 
that the sA3 has similar antiviral activity as A3 against a human RV strain, Wa, in 
a human intestinal cell line (HT29.f8).  
Initial TEM studies in the Parr laboratory (Lockwood, 2016; Caleb Witcher, 
2017) demonstrated intracellular RV particles of two size populations. The two 
populations observed consisted of a more mature nonenveloped (neRV) 
population that are of similar sizes of mature infectious RV particles, and the less 
mature enveloped (eRV) as previously described in the literature (Estes and 
Greenberg, 2013). At the same time point, TRPS analysis of the supernatants 
showed extracellular nanoparticles (50-150nm) using the Izon qNano system that 
had relatively equal number of extracellular particles among the treatments with 
and without arachidins. However, the size distribution of the particles varied 
significantly between treatments. This suggests that some of the nanoparticles 
that are released from RV-infected cells maybe infectious RV particles as these 
supernatants produced more infectious RV particles (~74nm) than the arachidin 
treated cells (~116-117nm) as shown with the plaque forming assays. Previous 
studies infecting Caco-2 cells with RRV (rhesus monkey rotavirus) have shown 
the presence of extracellular vesicles (EVs) composed of exosomes and 




centrifugation (Barreto et al., 2010; Bautista et al., 2015). A recent manuscript 
has reviewed data that show Picornaviridae and Hepeviridae produce virus 
particles in fully host-derived lipid bilayers that  resemble extracellular vesicles 
(EV), which are 50 nm–1 μm vesicles released by infected cells (van der Grein et 
al., 2018). These studies indicate that some of the nanoparticles that our study 
has measured maybe EVs, therefore they will be further characterized in future 
studies.   
The nucleus/cytoplasm ratio data obtained using TEM and 
immunofluorescent whole cell studies supported our hypothesis that there was a 
modulation of the apoptosis pathway with the addition of the arachidins to RV 
infected HT29.f8 cells. These characteristics of apoptosis have been previously 
reported in another RV study. This implies modulations cell signaling pathways 
by A3 and sA3 to achieve cellular homeostasis.  
Multiple associations exist between autophagy and apoptosis signaling 
pathways (Dang et al., 2015; Kroemer & Levine, 2009; Nikoletopoulou et al., 
2013; Wang et al., 2015). Previous reports have shown that RV infections lead to 
cell death using the apoptosis cellular death pathway (Frias et al. , 2012). 
However, recent studies have suggested that the RV nonstructural protein 4 
(NSP4) alone triggers the cells to produce autophagosomes, suggesting a 
change to an autophagy pathway that may be arrested at the autophagosomal 




viral and pro-viral pathway, and the role of autophagy depends on the virus, the 
cell type, and the cellular environment (Jackson, 2015). The presence of both 
pathways as observed with TEM, led to exploration of the molecular and 
functional connections between the apoptosis and autophagy pathways in RV-
infected HT29.f8 cells with and without the arachidins. The qRT-PCR studies 
conducted at 6, 7, 8, and 9hpi did not show significant fold changes in the 
expression of select autophagy and apoptosis. However, the upregulation of 
active caspase 3 and 7 proteins at 12hpi detected using the Apo One 3/7 assay 
suggests the involvement of the apoptosis pathway that is altered by A3 and sA3. 
Future studies will explore these pathways on a more global scale using the RT2 
apoptosis and autophagy assays. For example, the RT² Profiler™ PCR Array 
Human Apoptosis from Qiagen (Qiagen Inc., Germantown, MD) in which 84 or 
370 genes of interest can be screened at the same time giving a much more 
global picture of what is happening in the pathways could be used.  
 The Apo ONE Caspase-3/7 assay time course study revealed that by 
12hpi there was a significant increase in the initiator caspase 3 and 7 activity. 
Later time points revealed a drastic reduction in caspase 3 and 7 activity. It was 
noteworthy that there was a statistical decrease in caspae-3/7 activity with the 
addition of either arachidin to RV infections; however, the arachidins alone had a 
significantly higher caspase-3/7 activity than any of the test samples. This 




drug screening study has identified the PI3K/mTOR inhibitor, BEZ235, as a 
regulator of both influenza virus production and cellular metabolic homeostasis 
(Smallwood, et al, 2017).  This study shows a potential antiviral agent that affects 
both an RNA virus’ replication and cellular homeostasis that suggests a 
mechanism of action that modulates cellular homeostasis and inhibits viral 
infections. This type of therapeutic agent could be very efficient against viral 
infections without the side effects of causing viruses to mutate and evade the 
antiviral drugs or vaccines. 
Altogether, the data suggests the addition of A3 or sA3 to RV infections 
has a protective effect on host cells, and that a crosstalk between apoptosis and 
autophagy inhibits RV morphogenesis.  These findings indicate the possibility 
that RV modulates the switch between autophagy and apoptosis to facilitate their 
own replication in untreated cells, and suggests that A3 and sA3 restore cellular 
homeostasis, producing a protective response that has potential therapeutic 
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